Patents by Inventor Anna Arnal
Anna Arnal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230323356Abstract: This study describes a method to determine the likelihood of the development of metastasis in a subject suffering from cancer, in addition to a method to design a customized therapy in a subject suffering from cancer, in particular breast, colon, lung, kidney and thyroid cancer, based on the determination of the expression level of one or more genes whose expression is modulated by an increase in c-MAF expression. It also describes a method for the identification of marker genes with a propensity for metastatic cancer based on inducing the modulation of the c-MAF expression Finally, the use of PTHLH and PODXL inhibitors and RERG activators in the treatment and/or prevention of the cancer, in particular breast, colon, lung, kidney and thyroid cancer.Type: ApplicationFiled: January 13, 2023Publication date: October 12, 2023Inventors: Roger GOMIS, Anna ARNAL, Maria TARRAGONA, Milica PAVLOVIC, Evarist PLANET
-
Patent number: 11591599Abstract: This study describes a method to determine the likelihood of the development of metastasis in a subject suffering from cancer, in addition to a method to design a customized therapy in a subject suffering from cancer, in particular breast, colon, lung, kidney and thyroid cancer, based on the determination of the expression level of one or more genes whose expression is modulated by an increase in c-MAF expression. It also describes a method for the identification of marker genes with a propensity for metastatic cancer based on inducing the modulation of the c-MAF expression Finally, the use of PTHLH and PODXL inhibitors and RERG activators in the treatment and/or prevention of the cancer, in particular breast, colon, lung, kidney and thyroid cancer.Type: GrantFiled: April 3, 2018Date of Patent: February 28, 2023Assignees: Fundació Institut de Recerca Biomèdica (IRB Barcelona), Institució Catalana de Recerca i Estudis AvançaisInventors: Roger Gomis, Anna Arnal, Maria Tarragona, Milica Pavlovic, Evarist Planet
-
Publication number: 20220049316Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER-breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER-breast cancer metastasis.Type: ApplicationFiled: July 26, 2021Publication date: February 17, 2022Applicants: FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA), INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATSInventors: Roger GOMIS, Maria TARRAGONA, Anna ARNAL, Milica PAVLOVIC
-
Publication number: 20210317534Abstract: The present invention relates to a method for the prognosis of bone metastasis in cancer which comprises using a probe to determine if a gene of interest is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise using a probe to determine the expression level of a gene of interest, or the amplification or translocation of a gene of interest. The invention also relates to a method for predicting early bone metastasis in a subject suffering cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of cancer metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the invention relates to a method for typing of a subject suffering cancer and for classifying a subject from cancer into a cohort.Type: ApplicationFiled: April 27, 2021Publication date: October 14, 2021Inventors: Roger GOMIS, Evarist PLANET, Milica PAVLOVIC, Anna ARNAL, Maria TARRAGONA
-
Patent number: 11072831Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER? breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER? breast cancer metastasis.Type: GrantFiled: July 6, 2018Date of Patent: July 27, 2021Assignees: FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA), INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATSInventors: Roger Gomis, Maria Tarragona, Anna Arnal, Milica Pavlovic
-
Publication number: 20210190784Abstract: The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis.Type: ApplicationFiled: December 1, 2020Publication date: June 24, 2021Inventors: Roger GOMIS, Milica PAVLOVIC, Evarist PLANET, Anna ARNAL, Maria TARRAGONA
-
Patent number: 10866241Abstract: The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis.Type: GrantFiled: May 30, 2017Date of Patent: December 15, 2020Assignees: INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS, FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)Inventors: Roger Gomis, Milica Pavlovic, Evarist Planet, Anna Arnal, Maria Tarragona
-
Publication number: 20190309299Abstract: This study describes a method to determine the likelihood of the development of metastasis in a subject suffering from cancer, in addition to a method to design a customized therapy in a subject suffering from cancer, in particular breast, colon, lung, kidney and thyroid cancer, based on the determination of the expression level of one or more genes whose expression is modulated by an increase in c-MAF expression. It also describes a method for the identification of marker genes with a propensity for metastatic cancer based on inducing the modulation of the c-MAF expression Finally, the use of PTHLH and PODXL inhibitors and RERG activators in the treatment and/or prevention of the cancer, in particular breast, colon, lung, kidney and thyroid cancer.Type: ApplicationFiled: April 3, 2018Publication date: October 10, 2019Applicants: Fundacio Institut de Recerca Biomedica (IRB Barcelona), Institucio Catalana de Recerca I Estudis AvancatsInventors: Roger GOMIS, Anna Arnal, Maria Tarragona, Milica Pavlovic, Evarist Planet
-
Publication number: 20190169693Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER? breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER? breast cancer metastasis.Type: ApplicationFiled: July 6, 2018Publication date: June 6, 2019Applicants: FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA), INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATSInventors: Roger GOMIS, Maria Tarragona, Anna Arnal, Milica Pavlovic
-
Patent number: 10047398Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER? breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER? breast cancer metastasis.Type: GrantFiled: October 5, 2011Date of Patent: August 14, 2018Assignees: Fundacio Institut de Recerca Biomedica (IRB Barcelona), Institucio Catalana de Recerca I Estudis AvancatsInventors: Roger Gomis, Maria Tarragona, Anna Arnal, Milica Pavlovic
-
Publication number: 20170370935Abstract: The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis.Type: ApplicationFiled: May 30, 2017Publication date: December 28, 2017Applicants: Fundació Institut de Recerca Biomédica (IRB Barcelona), Institució Catalana de Recerca I Estudis AvancatsInventors: Roger GOMIS, Milica Pavlovic, Evarist Planet, Anna Arnal, Maria Tarragona
-
Patent number: 9702878Abstract: The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis.Type: GrantFiled: March 15, 2013Date of Patent: July 11, 2017Assignees: Fundació Institut de Recera Biomèdica (IRB Barcelona), Institució Catalana de Recerca I Estudis AvançatsInventors: Roger Gomis, Milica Pavlovic, Evarist Planet, Anna Arnal, Maria Tarragona
-
Publication number: 20170101683Abstract: The present invention relates to a method for the prognosis of bone metastasis in HER2+ breast cancer, which comprises determining if the MAF gene is amplified in a primary tumor sample. Likewise, the present invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the MAF gene expression level, amplification or translocation. The present invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The present invention also relates to a c-Maf inhibitor as therapeutic agent for use in the treatment of HER2+ breast cancer metastasis. The present invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the present invention relates to a method for typing of a subject suffering breast cancer and for classifying a subject from breast cancer into a cohort.Type: ApplicationFiled: October 7, 2014Publication date: April 13, 2017Applicants: Fundació Institut de Recerca Biomèdica (IRB Barcelona), Institució Catalana de Recerca i Estudis AvançatsInventors: Roger GOMIS, Evarist PLANET, Milica Pavlovic, Anna ARNAL, Maria TARRAGONA
-
Publication number: 20170002357Abstract: This study describes a method to determine the likelihood of the development of metastasis in a subject suffering from cancer, in addition to a method to design a customized therapy in a subject suffering from cancer, in particular breast, colon, lung, kidney and thyroid cancer, based on the determination of the expression level of one or more genes whose expression is modulated by an increase in c-MAF expression. It also describes a method for the identification of marker genes with a propensity for metastatic cancer based on inducing the modulation of the c-MAF expression Finally, the use of PTHLH and PODXL inhibitors and RERG activators in the treatment and/or prevention of the cancer, in particular breast, colon, lung, kidney and thyroid cancer.Type: ApplicationFiled: February 3, 2016Publication date: January 5, 2017Inventors: Roger GOMIS, Anna Arnal, Maria Tarragona, Milica Pavlovic, Evarist Planet
-
Publication number: 20160139126Abstract: The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis.Type: ApplicationFiled: March 15, 2013Publication date: May 19, 2016Applicants: Fundació Institut de Recerca Biomèdica (IRB Barcelona), Institució Catalana de Recerca i Estudis AvançatsInventors: Roger Gomis, Milica Pavlovic, Evarist Planet, Anna Arnal, Maria Tarragona
-
Publication number: 20160040247Abstract: This study describes a method to determine the likelihood of the development of metastasis in a subject suffering from cancer, in addition to a method to design a customized therapy in a subject suffering from cancer, in particular breast, colon, lung, kidney and thyroid cancer, based on the determination of the expression level of one or more genes whose expression is modulated by an increase in c-MAF expression. It also describes a method for the identification of marker genes with a propensity for metastatic cancer based on inducing the modulation of the c-MAF expression Finally, the use of PTHLH and PODXL inhibitors and RERG activators in the treatment and/or prevention of the cancer, in particular breast, colon, lung, kidney and thyroid cancer.Type: ApplicationFiled: March 14, 2014Publication date: February 11, 2016Applicants: Fundació Institut de Recerca Biomèdica (IRB Barcelona), Institució Liuís Companys, 23Inventors: Roger GOMIS, Anna ARNAL, Maria TARRAGONA, Milica PAVLOVIC, Evarist PLANET
-
Publication number: 20160032400Abstract: The present invention relates to a method for the prognosis of bone metastasis in cancer which comprises using a probe to determine if a gene of interest is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise using a probe to determine the expression level of a gene of interest, or the amplification or translocation of a gene of interest. The invention also relates to a method for predicting early bone metastasis in a subject suffering cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of cancer metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the invention relates to a method for typing of a subject suffering cancer and for classifying a subject from cancer into a cohort.Type: ApplicationFiled: March 14, 2014Publication date: February 4, 2016Applicants: Fundació Institut de Recerca Biomèdica (IRB Barcelona), Institucio Catalana de Recerca i Estudis AvancatsInventors: Roger GOMIS, Evarist PLANET, Milica PAVLOVIC, Anna ARNAL, Maria TARRAGONA
-
Publication number: 20150293100Abstract: The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis.Type: ApplicationFiled: March 15, 2013Publication date: October 15, 2015Applicants: Fundacio' Institut de Recerca Biomedica (IRB Marvelona), Institucio Cata;ana de Recerca i Estudis AvancatsInventors: Roger Gomis, Milica Pavlovic, Evarist Planet, Anna Arnal, Maria Tarragona
-
Publication number: 20140314792Abstract: This study describes a method to determine the likelihood of the development of metastasis in a subject suffering from cancer, in addition to a method to design a customized therapy in a subject suffering from cancer, in particular breast, colon, lung, kidney and thyroid cancer, based on the determination of the expression level of one or more genes whose expression is modulated by an increase in c-MAF expression. It also describes a method for the identification of marker genes with a propensity for metastatic cancer based on inducing the modulation of the c-MAF expression Finally, the use of PTHLH and PODXL inhibitors and RERG activators in the treatment and/or prevention of the cancer, in particular breast, colon, lung, kidney and thyroid cancer.Type: ApplicationFiled: March 14, 2014Publication date: October 23, 2014Inventors: Roger GOMIS, Anna Arnal, Maria Tarragona, Milica Pavlovic, Evarist Planet
-
Publication number: 20140057796Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER? breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER? breast cancer metastasis.Type: ApplicationFiled: October 5, 2011Publication date: February 27, 2014Applicants: Fundació Privada Institució Catalana De Recerca I Estudis Avançats, Fundació Privada Institut De Recerca BiomèdicaInventors: Roger Gomis, Maria Tarragona, Anna Arnal, Milica Pavlovic